These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35384604)

  • 1. Targeting papain-like protease for broad-spectrum coronavirus inhibition.
    Yuan S; Gao X; Tang K; Cai JP; Hu M; Luo P; Wen L; Ye ZW; Luo C; Tsang JO; Chan CC; Huang Y; Cao J; Liang R; Qin Z; Qin B; Yin F; Chu H; Jin DY; Sun R; Chan JF; Cui S; Yuen KY
    Protein Cell; 2022 Dec; 13(12):940-953. PubMed ID: 35384604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective inhibition of coronavirus replication by
    Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-cov-2 PLpro.
    Liu X; Zheng M; Zhang H; Feng B; Li J; Zhang Y; Zhang J; Zhao N; Li C; Song N; Song B; Yang D; Chen J; Qi A; Zhao L; Luo C; Zang Y; Liu H; Li J; Zhang B; Zhou Y; Zheng J
    Antiviral Res; 2024 Aug; 228():105944. PubMed ID: 38914283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
    Lee H; Lei H; Santarsiero BD; Gatuz JL; Cao S; Rice AJ; Patel K; Szypulinski MZ; Ojeda I; Ghosh AK; Johnson ME
    ACS Chem Biol; 2015 Jun; 10(6):1456-65. PubMed ID: 25746232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity.
    Shin D; Mukherjee R; Grewe D; Bojkova D; Baek K; Bhattacharya A; Schulz L; Widera M; Mehdipour AR; Tascher G; Geurink PP; Wilhelm A; van der Heden van Noort GJ; Ovaa H; Müller S; Knobeloch KP; Rajalingam K; Schulman BA; Cinatl J; Hummer G; Ciesek S; Dikic I
    Nature; 2020 Nov; 587(7835):657-662. PubMed ID: 32726803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.
    Shan H; Liu J; Shen J; Dai J; Xu G; Lu K; Han C; Wang Y; Xu X; Tong Y; Xiang H; Ai Z; Zhuang G; Hu J; Zhang Z; Li Y; Pan L; Tan L
    Cell Chem Biol; 2021 Jun; 28(6):855-865.e9. PubMed ID: 33979649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
    Stasiulewicz A; Maksymiuk AW; Nguyen ML; Bełza B; Sulkowska JI
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.
    Kiba Y; Tanikawa T; Kitamura M
    Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING.
    Cao D; Duan L; Huang B; Xiong Y; Zhang G; Huang H
    Sci Signal; 2023 May; 16(783):eadd0082. PubMed ID: 37130168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
    Valipour M
    Eur J Med Chem; 2022 Oct; 240():114572. PubMed ID: 35797899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoronavirus activity of rhizome of Dryopteris crassirhizoma via multistage targeting of virus entry and viral proteases, Mpro and PLpro.
    Habib M; Jin YH; Kim Y; Min JS; Ha IJ; Lee SM; Kwon S
    J Ethnopharmacol; 2024 Oct; 333():118490. PubMed ID: 38925321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.
    Narayanan A; Narwal M; Majowicz SA; Varricchio C; Toner SA; Ballatore C; Brancale A; Murakami KS; Jose J
    Commun Biol; 2022 Feb; 5(1):169. PubMed ID: 35217718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chimeric virus-mouse model system for evaluating the function and inhibition of papain-like proteases of emerging coronaviruses.
    Deng X; Agnihothram S; Mielech AM; Nichols DB; Wilson MW; StJohn SE; Larsen SD; Mesecar AD; Lenschow DJ; Baric RS; Baker SC
    J Virol; 2014 Oct; 88(20):11825-33. PubMed ID: 25100850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease.
    Yang X; Chen X; Bian G; Tu J; Xing Y; Wang Y; Chen Z
    J Gen Virol; 2014 Mar; 95(Pt 3):614-626. PubMed ID: 24362959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease.
    Liu W; Wang J; Wang S; Yue K; Hu Y; Liu X; Wang L; Wan S; Xu X
    Bioorg Chem; 2023 Nov; 140():106830. PubMed ID: 37683544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus.
    Báez-Santos YM; Mielech AM; Deng X; Baker S; Mesecar AD
    J Virol; 2014 Nov; 88(21):12511-27. PubMed ID: 25142582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19.
    Hersi F; Sebastian A; Tarazi H; Srinivasulu V; Mostafa A; Allayeh AK; Zeng C; Hachim IY; Liu SL; Abu-Yousef IA; Majdalawieh AF; Zaher DM; Omar HA; Al-Tel TH
    Eur J Med Chem; 2023 Jun; 254():115380. PubMed ID: 37075625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring Cannabinoids as Potential Inhibitors of SARS-CoV-2 Papain-like Protease: Insights from Computational Analysis and Molecular Dynamics Simulations.
    Holmes J; Islam SM; Milligan KA
    Viruses; 2024 May; 16(6):. PubMed ID: 38932170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
    Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S
    Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.